

Sorrento Therapeutics, Inc.  
Form 8-K  
May 30, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 23, 2014**

**SORRENTO THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
**of incorporation or organization)**

**001-36150**  
**(Commission**  
**File Number)**  
**6042 Cornerstone Ct. West, Suite B**

**33-0344842**  
**IRS Employer**  
**Identification No.)**

Edgar Filing: Sorrento Therapeutics, Inc. - Form 8-K

**San Diego, CA 92121**

**(Address of principal executive offices)**

**Registrant's telephone number, including area code: (858) 210-3700**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On May 23, 2014, Sorrento Therapeutics, Inc. ( Sorrento or the Company ) promoted Mike Royal to Executive Vice President of Clinical and Regulatory Affairs.

Dr. Royal joined Sorrento in March 2014 as a Senior Vice President of Clinical Development. Dr. Royal brings more than 20 years of drug development experience where he was a key contributor to over a dozen ANDAs and several NDAs, most recently Zalviso at AcelRx and Ofirme<sup>®</sup> at Cadence (currently being acquired by Mallinckrodt). He has managed clinical operations and regulatory activities across multiple trials and multiple countries for both small molecule and biologic products. He is board certified in internal medicine, pain medicine, anesthesiology with additional certification in pain management, addiction medicine, and legal medicine. He has authored or co-authored more than 170 papers and abstracts. Previously, he was a clinical adjunct professor at the University of California San Diego and the University of Oklahoma Medical School, and a faculty member at the University of Pittsburgh Medical Center. He has also worked at Elan, Alpharma and Solstice Neuroscience. He graduated from the Massachusetts Institute of Technology in synthetic organic chemistry. He earned his M.D. from the Massachusetts Medical School, law degree from the University of Maryland School of Law, and MBA from TRIUM (NYU-Stern, HEC-Paris and the London School of Economics).

On May 23, 2014, Dr. Vuong Trieu resigned as Chief Scientific Officer of the Company. Dr. Trieu will remain with the Company as a director.

**Item 8.01 Other Events.**

On May 30, 2014, the Company issued a press release announcing that Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento, will present at the Jefferies 2014 Global Healthcare Conference. The Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 8.01, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.

**Item 9.01 Financial Statements and Exhibits.**  
**(d) Exhibits.**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release dated May 30, 2014

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 30, 2014

SORRENTO THERAPEUTICS, INC.

By: /s/ Richard Vincent

Name: Richard Vincent

Title: Executive Vice President, Chief  
Financial Officer and Secretary